Suppr超能文献

转移抑制基因Raf激酶抑制蛋白(RKIP)是前列腺癌中一种新的预后标志物。

Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.

作者信息

Fu Zheng, Kitagawa Yasuhide, Shen Ronglai, Shah Rajal, Mehra Rohit, Rhodes Daniel, Keller Peter J, Mizokami Atsushi, Dunn Rodney, Chinnaiyan Arul M, Yao Zhi, Keller Evan T

机构信息

Department of Urology, University of Michigan, Ann Arbor, Michigan 48109-0940, USA.

出版信息

Prostate. 2006 Feb 15;66(3):248-56. doi: 10.1002/pros.20319.

Abstract

BACKGROUND

Diminished expression of Raf kinase inhibitor protein (RKIP), an inhibitor of the Raf signaling cascade, promotes prostate cancer (PCa) metastasis in a murine model, suggesting that it is a metastasis suppressor gene. However, the prognostic significance of RKIP expression and its association with metastasis in PCa patients is unknown.

METHODS

To investigate RKIP protein expression is a prognostic marker in PCa we performed immunohistochemical staining for RKIP expression in tissue microarrays consisting of 758 non-neoplastic prostate tissues, primary tumors and metastases from 134 PCa patients. The Cox proportional-hazards model was used to adjust for covariates including Gleason score, tumor volume, tumor weight, clinical stage, digital rectal exam findings, serum PSA level and surgical margins.

RESULTS

RKIP expression was low in approximately 5%, 48%, and 89% of non-neoplastic prostate, primary tumors and metastases, respectively. Low RKIP expression in primary tumors was a strong positive predictive factor for PCa recurrence based on PSA levels. In patients whose primary tumors expressed high RKIP levels, the 7-year PSA recurrence rate was <10%; whereas in patients with tumors with low RKIP expression the recurrence rate was 50% (P<0.001). Multivariate analysis revealed RKIP was an independent prognostic factor (P<0.001).

CONCLUSION

In contrast to increased expression of pro-tumorigenic genes, these results demonstrate decreased protein expression of a gene, for example, RKIP, can serve as a prognostic marker in PCa patients.

摘要

背景

Raf激酶抑制蛋白(RKIP)是Raf信号级联反应的一种抑制剂,其表达降低可促进小鼠模型中的前列腺癌(PCa)转移,提示它是一种转移抑制基因。然而,RKIP表达在PCa患者中的预后意义及其与转移的关系尚不清楚。

方法

为了研究RKIP蛋白表达是否是PCa的预后标志物,我们对包含758个非肿瘤性前列腺组织、134例PCa患者的原发性肿瘤和转移灶的组织芯片进行了RKIP表达的免疫组化染色。采用Cox比例风险模型对协变量进行校正,包括Gleason评分、肿瘤体积、肿瘤重量、临床分期、直肠指检结果、血清PSA水平和手术切缘。

结果

RKIP表达在非肿瘤性前列腺组织、原发性肿瘤和转移灶中分别约有5%、48%和89%较低。原发性肿瘤中RKIP低表达是基于PSA水平的PCa复发的强阳性预测因子。原发性肿瘤RKIP表达水平高的患者,7年PSA复发率<10%;而RKIP表达低的肿瘤患者复发率为50%(P<0.001)。多因素分析显示RKIP是一个独立的预后因素(P<0.001)。

结论

与促肿瘤基因表达增加相反,这些结果表明一个基因(如RKIP)的蛋白表达降低可作为PCa患者的预后标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验